Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 7:2018:6240467.
doi: 10.1155/2018/6240467. eCollection 2018.

Combination Immunotherapy Approaches for Pancreatic Cancer Treatment

Xianliang Cheng  1 , Gang Zhao  2 , Yunqi Zhao  1
Affiliations
Review

Combination Immunotherapy Approaches for Pancreatic Cancer Treatment

Xianliang Cheng et al. Can J Gastroenterol Hepatol. .

Abstract

Pancreatic ductal adenocarcinoma is a lethal malignant disease with a very low medium survival. Currently, metastatic pancreatic cancer poorly responds to conventional treatments and exhibits an acute resistance to most chemotherapy. Few approaches have been shown to be effective for metastatic pancreatic cancer treatment. Novel therapeutic approaches to treat patients with pancreatic adenocarcinoma are in great demand. Last decades, immunotherapies have been evaluated in clinical trials and received great success in many types of cancers. However, it has very limited success in treating pancreatic cancer. As pancreatic cancer poorly responds to many single immunotherapeutic agents, combination immunotherapy was introduced to improve efficacy. The combination therapies hold great promise for enhancing immune responses to achieve better therapeutic effects. This review summarizes the existing and potential combination immunotherapies for the treatment of pancreatic cancer.

PubMed Disclaimer

References

    1. Yadav D., Lowenfels A. B. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252–1261. doi: 10.1053/j.gastro.2013.01.068. - DOI - PMC - PubMed
    1. Kamisawa T., Wood L. D., Itoi T., Takaori K. Pancreatic cancer. Lancet (London, England) 2016;388(10039):73–85. doi: 10.1016/S0140-6736(16)00141-0. - DOI - PubMed
    1. Vaccaro V., Sperduti I., Milella M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine. 2011;365(8):768–769. doi: 10.1056/NEJMc1107627. - DOI - PubMed
    1. Morgan R. A., Yang J. C., Kitano M., Dudley M. E., Laurencot C. M., Rosenberg S. A. Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy. 2010;18(4):843–851. doi: 10.1038/mt.2010.24. - DOI - PMC - PubMed
    1. Berger C., Sommermeyer D., Hudecek M., et al. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunology Research. 2015;3(2):206–216. doi: 10.1158/2326-6066.cir-14-0163. - DOI - PMC - PubMed

MeSH terms